# Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+

> **NCT02936089** · NA · COMPLETED · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 207 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Risk Stratification

## Interventions

- **OTHER:** Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT)
- **OTHER:** Consolidation with auto-HSCT or HLA-matched HSCT
- **OTHER:** allogeneic HSCT

## Key facts

- **NCT ID:** NCT02936089
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2023-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02936089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02936089, "Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02936089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*